论文部分内容阅读
目的:分析美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎的临床疗效。方法:随机抽取本院收治的110例溃疡性结肠炎患者,按照药物不同分为两组,各55例,A组患者采取美沙拉嗪治疗,B组患者采取柳氮磺砒啶治疗,对比两组患者治疗效果。结果:A组治疗总有效率96.4%高于B组总有效率83.6%,腹痛、腹泻、脓血便等症状改善时间较B组短,治疗后症状评分明显低于B组,不良反应发生率1.8%低于B组不良反应发生率12.7%,差异具有统计学意义(P<0.05)。结论:美沙拉嗪与柳氮磺吡啶治疗溃疡性结肠炎均具有显著疗效,但美沙拉嗪安全性高于柳氮磺砒啶。
Objective: To analyze the clinical efficacy of mesalazine and sulfasalazine in the treatment of ulcerative colitis. Methods: A total of 110 patients with ulcerative colitis admitted to our hospital were selected randomly and divided into two groups according to different drugs: 55 cases in group A, mesalazine in group A, and sulfasalazine in group B, Group patients treatment effect. Results: The total effective rate in group A was 96.4% higher than that in group B (83.6%). The improvement time of abdominal pain, diarrhea and pus and blood stool was shorter than that in group B, and the symptom score was significantly lower than that in group B after treatment. The incidence of adverse reactions was 1.8 The incidence of% adverse reactions in group B was 12.7%, the difference was statistically significant (P <0.05). Conclusion: Both mesalazine and sulfasalazine have a significant therapeutic effect on ulcerative colitis, but mesalazine is more safe than sulfasalazine.